anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In addition to the increase in obesity in adult and children, there has been a significant increase in birth weights over the last 2 decades. Based on our preliminary data, maternal pre-gravid obesity is the strongest risk factor for neonatal as well as adolescent obesity. The long-term goals of our research are to examine therapeutic strategies to decrease fetal adiposity. Obesity and pregnancy are both insulin resistant conditions associated with chronic low-grade inflammation. Therefore, we hypothesize that n-3 PUFA dietary supplements during pregnancy will act as insulin sensitizers decreasing peripheral insulin resistance and inflammation. If correct this mechanism should decrease availability of maternal nutrients to the fetus and subsequently reduce adiposity at birth. We plan a prospective randomized double blind control trial of n-3 PUFA supplementation and placebo in overweight/obese women, with a previous cesarean delivery, initiated in early pregnancy and maintained throughout pregnancy. This proposal has two specific aims. Specific aim 1 is to evaluate the effect of n-3 PUFA supplementation on maternal insulin sensitivity. Measures of maternal insulin sensitivity and lipid metabolism will be made using the ISogtt, indirect calorimetry body composition (BODPOD) and plasma lipid profile at baseline and after dietary intervention.

Specific aim 2 will assess the effect of n-3 PUFA on the inflammatory status in overweight/obese pregnant women. We hypothesize that n-3 PUFA supplementation decreases chronic inflammation during pregnancy by preventing monocyte activation and accumulation of macrophages in WAT thus lowering systemic concentration of pro-inflammatory cytokines. We plan to characterize the longitudinal changes in circulating monocytes and plasma adipokines in order to define the inflammatory patterns in both groups over time. We will also determine the abundance and phenotype of macrophages infiltrating WAT using flow cytometry, immunohistochemistry and gene expression profiling. Furthermore, the role of PPARγ as a central target of n-3 PUFA action to regulate insulin sensitivity will be examined by characterizing the expression of PPARγ in WAT of both supplemented and control groups. Additionally, we will investigate the direct affect of n-3 PUFA on the expression of adiponectin and PPARγ regulated genes in primary cultured adipocytes.

In summary, this proposal combines both clinical and molecular methodologies in an overweight/obese subject population in order to assess the effect of n-3 PUFA on inflammation and insulin resistance. Preliminary data will also be obtained on fetal body composition in order to later address the prevention of the long term adverse effects (developmental programming) of maternal obesity in the developing fetus.
PURPOSE:To provide the subject low toxic, and strong scavenger useful as a preventive/therapeutic agent for various diseases due to active oxygen radicals. CONSTITUTION:The objective scavenger containing, as active ingredient, a pyrroloquinoline quinone(PQQ) ester of formula I (R1-R3 are such H, alkyl, alkenyl or benzye), e.g. PQQ trimethyl ester. The PQQ ester can easily be obtained by conventional reaction of PQQ or its salt with an alcohol. A PQQ mono- or diester can also be obtained by hydrolysis of the corresponding PQQ triester under basic conditions or by reaction of the corresponding PQQ monoester with an alcohol, etc., at appropriate temperature for appropriate time. The PQQ ester can be administered either orally or parenterally.
All prescriptions using this product shall be pursuant to state statutes as applicable. This product may be administered only under a physician’s supervision. There are no implied or explicit claims on the therapeutic equivalence.   
Store at 25ºC (77ºF); excursions permitted to 15º-30ºC (59º-86º F). See USP Controlled Room Temperature. Protect from freezing.
PURPOSE:To produce a long wavelength ultraviolet absorber having excellent ultraviolet shielding properties and suitable for use in a cosmetic preparation, by mixing a particular dibenzoylmethane deriv. and a polyvalent metal oxide in a solvent. CONSTITUTION:A substd. phthalic acid monoester of formula I [wherein R is methyl or ethyl; Z is OH, a 1-24C straight-chain or branched aliph. hydrocarbon residue, a 1-24C alkoxy, a polyoxyalkylene (2C or 3C) oxide; and m is 0-3] is condensed with a substd. acetophenone of formula II (wherein Y is Z; and n is 0-3) in the presence of a basic catalyst, thereby obtaining a compd. of formula III. The compd. (III) is esterified, thereby obtaining a dibenzoylmethane derive. (A) of formula IV [wherein X is H, a metal cation, an org. cation, a 1-24C straight-chain or branched aliph. hydrocarbon residue, or a polyoxyalkylene (2C or 3C) oxide]. Component (A) is mixed with a polyvalent metal oxide (e.g., ZnO) having a particle size up to 100mum in a wt. ratio of 1:0.01-100 in water and/or a lower alcohol.
A therapeutic nasal inhalant for using bioflavanoids as a topical antioxidant. The therapeutic nasal inhalant includes a method for making a therapeutic nasal inhalant composition for treating nasal mucosa. The method comprises the steps of mixing together two cups of water, one teaspoon of baking soda, one teaspoon of sodium chloride, and four milligrams of vitamin C to form a mixture. Mixing a bioflavanoid with the mixture. Allowing the mixture to stand. Filtering the mixture. Allowing the mixture to stand for a second time. Filtering the mixture.
NS: Normal Saline. Patients in the NS treatment arm will receive fluid therapy based on normal saline for a minimum of 48 hours.
Acrolein is a ubiquitous gaseous air pollutant and endogenous toxicant, which poses strong risk for oxidative stress-related diseases such as cardiovascular disease. Adenosine has been identified as potential therapeutic agent for age-related cardiovascular disease, while the molecular mechanisms underlying its cardioprotection remain elusive. In the present study, we investigated the myocardial protective effects and the mechanism of adenosine on acrolein-induced toxicity in H9c2 cells and primary neonatal rat cardiomyocytes. We found that acrolein caused apoptosis of cardiomyocytes resulting from oxidative damage, autophagy defect, and mitochondrial dysfunction, as evidenced by loss of mitochondrial membrane potential, impairment of mitochondrial biogenesis, dynamics, and oxidative phosphorylation, decrease of mitochondrial deoxyribonucleic acid (mtDNA) copy number and adenosine 5'-triphosphate (ATP) production. Adenosine pretreatment protected against acrolein-induced cardiotoxicity by maintaining mitochondrial homeostasis, activating the phase II detoxifying enzyme system, promoting autophagic flux, and alleviating mitochondrial-dependent apoptosis. We further demonstrated that the up-regulation of forkhead box protein O1 (FoxO1) mediated by extracellular regulated protein kinases (ERK) activation contributes to the cardioprotection of adenosine. These results expand the application of adenosine in cardioprotection to preventing myocardial damages induced by environmental pollutant acrolein exposure, and uncover the adenosine-ERK-FoxO1 axis as the underlying mechanism mediating the protection of mitochondrial homeostasis, Nrf2-mediated antioxidant defense and autophagic flux, shedding light on the better understanding about the pathological mechanism of cardiovascular disease caused by environmental pollutants and applications of adenosine in cardioprotection.
Exposure to maternal depressive and anxious symptomatology in utero and after birth can affect child outcomes. One proposed mechanism is through changes in child stress hormone levels, however current studies present inconsistent findings, and further research is needed to better understand the impact of maternal mental health on child stress response. This study aims to add to the limited literature by analysing longitudinal data ranging from 24 weeks amenorrhea to 5 years postpartum among 281 mother-child pairs from the French EDEN mother-child birth cohort. Hair cortisol and cortisone data were collected from children at four time points: birth, 1, 3, and 5 years. Mothers reported depressive symptomatology via the Center for Epidemiologic Studies Depression Scale (CES-D) (at 24-weeks amenorrhea, 3-, and 5-year follow-up), and the Edinburgh Postnatal Depression Scale (EPDS) (at 4, 8 and 12 months postpartum). Prenatal anxiety symptomatology was measured via the State Anxiety Inventory (STAI) at 24 weeks amenorrhea. Group-based trajectory modelling indicated a 1-cluster classification of longitudinal child hair cortisol, cortisone and cortisol-to-cortisone ratio, as analyses did not reveal a classification by subgroups representing different child profiles. After inverse probability weighting, small effects showed prenatal depressive symptomatology was significantly associated to higher levels of child hair cortisone at one year. Prenatal anxiety symptomatology was significantly linked to higher levels of child cortisol measured at birth and cortisone at birth and at 1 year. Postpartum depressive symptomatology at 8 months was related to higher levels of cortisone among 3-year-olds. These effects were not moderated by child sex or maternal socio-economic status. Further research is needed to understand why there are associations at some time points and not others to determine any potential buffering factors.
Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Indium-111 Pentreotide (OctreoScan). The imaging protocol will consist of imaging at 4 and 24 hours after OctreoScan injection.
Participants will first complete the online screening and those who qualify to complete the study will be contacted via telephone (see above for telephone recruitment and consent procedure). After providing informed consent, on the first day, participants will be randomly assigned to either a TUS treatment or a TUS sham condition (placebo), and the study will be double blind. Participants in the TUS treatment condition (with sham or treatment unknown to both participant and experimenter) will have TUS stimulation at the right fronto-temporal area five times within seven days or ten times within fourteen days.

Participants will sign up for the first five sessions first but will be reminded participants may withdraw from the study at any time. Should participants choose to continue with the second week of treatment, participants will be scheduled for another five sessions. In other words, participants will have the option of completing 10 days of the procedure. The procedure does not differ between week 1 and week 2. However, participants will be compensated less for week 2. Participants will have the option to continue into week 2, as participants may find that the treatment is benefiting them. The first, fifth, and tenth days of the study will take approximately 2 hours and the second, third, fourth, sixth, seventh, eighth, and ninth will take only one hour.

In the sham condition, the ultrasound probe will be placed at the right fronto-temporal area five times over the course of seven days or ten times over the course of fourteen days without the stimulation. Prior research has shown that stimulation at this area induces positive mood change and is implicated in positive mood. On the first, middle, and last day of the procedure (day 1, 5, 10), EEG data will be collected. On the second, third, and fourth day as well as sixth through ninth days of the procedure EEG data will not be collected and only TUS stimulation will occur. Collecting EEG data at these points will allow for comparison of resting electrical brain profiles from the beginning of the study to the end of the study. Additionally, the investigators will assess state mood and rumination before and after TUS, as well as depressive and anxiety symptoms at the end of each day. The state mood and rumination will allow us to examine the mood effects of TUS, whereas the depressive and anxiety symptoms questionnaires will allow us to examine any changes in these important profiles over the course of the study.
The invention provides a mouth-scanning machine, a mouth-scanning system and a control method of the mouth-scanning machine. The motion sensor senses three motion changes corresponding to three axial directions according to the motion state of the oral sweeper. The storage unit stores three first variation threshold values corresponding to three axial directions. The processor judges whether the three motion changes are respectively less than or equal to three first change threshold values. When the processor judges that at least one of the three motion changes is smaller than or equal to three first change threshold values, the processor enables the image sensor and the optical projection module. When the processor judges that the three motion changes are all larger than the three first change threshold values, the processor disables at least one of the image sensor and the optical projection module. Therefore, the power consumption can be effectively reduced and the temperature rise can be avoided when the oral sweeper is in an idle state.
In this group, patients have already received paraffin treatment for their carpal tunnel syndrome. Paraffin treatment involves immersing the affected hand or hands in a mixture of heated paraffin wax. The sessions will last approximately 20-30 minutes per day, 5 days a week, for a total of 15 sessions for 3 weeks.
The purpose of this research is to determine if the oral form of a medication (tranexamic acid) to reduce bleeding can be used in place of an intravenous (IV) form.to learn the best way to give tranexamic acid: either a pill by mouth, or a solution by vein. Tranexamic acid is a medicine that reduces blood loss and reduces the need for blood transfusions in surgery. This drug is not experimental and has been used widely to treat patients in many settings, including orthopedic procedures, to reduce bleeding. This medication is now part of the standard of care at many centers in the U.S. and around the world. Orthopedic procedures have used iv tranexamic acid more often, but there are reasons to believe that the oral form may be at least equivalent and perhaps better at lower cost to the health care system. No other study has yet performed a systematic comparison to answer the question.
PURPOSE: To provide a compd. comprising a 1α,3β,25-trihydroxy-24- homocholesta-5,22-diene compd. as an intermediate for the synthesis of 1α,25- dihydroxy-24-homovitamin D 3  deriv. for the treatment for bone diseases.  
     CONSTITUTION: A bisnorcholanic acetate expressed by formula I (Ac is acetyl) is reduced by using hydrogenated aluminum lithium and then oxidized to obtain 1,4,6-trien-3-one, which is treated with an alkali hydrogen peroxide to obtain 1a,2a-epoxide. Then the compd. is reduced and then treated with chloromethyl methyl ether to obtain a dimethyloxymethyl ether, from which protecting groups of hydroxyl groups is removed. The compd. subjected to Swern oxidation to obtain an aldehyde expressed by formula II (MOMO is methoxymethoxy), which is then allowed to react with a vinyl bromide magnesium. Then the reaction product is allowed to react with an ortho-triethyl acetate and propionic acid to remove MOM groups for acetylation. Thus, the objective compd. expressed by formula III (R is H, a 1 to 4C acyl, benzoyl, etc.), is obtd. 
     COPYRIGHT: (C)1993,JPO
PURPOSE:To obtain a protein having strong antiphlogistic and analgesic activities and useful as an antiphlogistic agent, by extracting the stone of almond, apricot (Pruns armeniaca Linn. var. ansu Maxim.) or Japanese bush cherry (Prunus japonica Thunb.) with water. CONSTITUTION:The stones of almond, apricot or Japanese bush cherry are roughly crushed with a mixer, defatted with an oleophilic organic solvent, pulverized, and extracted with water at 10-60 deg.C, preferably at room temperature, for 1-5hr. The extract liquid is dialyzed or subjected to ultrafiltration, and two kinds of proteins are separated and purified from the remaining liquid by chromatography, or the extract liquid is added with a hydrophilic organic solvent, and a protein having high molecular weight is separated from the produced precipitate, and a protein having low molecular weight is obtained from the supernatant liquid. PR-AA having a molecular weight of 300,000-350,000 and PR-BA (10,000-15,000) are obtained from almond, PR-AB (250,000-350,000) and PR-BB (10,000-30,000) from apricot, and PR-AC (250,000-350,000) and PR- BC (10,000-15,000) from Japanese bush cherry.
The patients assigned to this group performed a self-treatment program that included three coordination exercises, two post-isometric relaxation (contraction-relaxation) and one self-traction. All exercises were performed in front of a mirror. It was performed every 3 hours, 5 times a day, for 4 weeks. The patient was instructed and supervised by a physiotherapist until they were executed correctly. All participants were provided with a video where the procedure and dosage of each exercise was described in detail.
Twenty subjects will receive an ultrasound guided interscalene nerve block using the Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. A Sham Block of in area of PECS "Pectoralis" block will be done to allow for assessment of the intervention. Using the Solution for Injection in Sham Block.
The recommended initial dose is 15 mg daily (7.5 mg b.i.d.). To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day, as needed. The maximum daily dosage should not exceed 60 mg per day. In clinical trials allowing dose titration, divided doses of 20 mg to 30 mg per day were commonly employed.

The bioavailability of buspirone is increased when given with food as compared to the fasted state (see CLINICAL PHARMACOLOGY). Consequently, patients should take buspirone in a consistent manner with regard to the timing of dosing; either always with or always without food.

When buspirone is to be given with a potent inhibitor of CYP3A4 the dosage recommendations described in the PRECAUTIONS: Drug Interactions section should be followed.
Disclosed are compositions and methods for treating and modifying surfaces and for enhancing delivery of active agents to surfaces treated therewith, wherein the compositions comprise siloxane polymers functionalized with pendant moieties comprising two or more anionic groups, at least one anionic group being a carboxy group. When applied to a suitable surface, the present composition forms a substantially hydrophobic coating of the anionic functionalized siloxane polymer on the treated surface. These polymers effectively deposit on surfaces that have cationic sites, which are capable of forming bonds or linkages with the anionic groups of the polymer. The treated surface becomes hydrophobic due to the deposition of the anionic functionalized siloxane polymer, which then imparts a variety of end use benefits to that surface such as ease of cleaning, soil release, stain removal and prevention, conditioning, etc. The anionic functionalized siloxane polymer further acts as a carrier to deposit active agents onto the surface and to improve retention and efficacy of the active agents on the treated surface. The present compositions are useful in a variety of applications including oral care, hair and skin care, personal care, cosmetics, and fabric and hard surface cleaning and conditioning.
Upon the detection of a positive microbiological finding for A. baumannii, the Eravacyclin group will receive eravacycline at a dose of 1 mg/kg every 12 hours for 60 minutes, along with a colistin bolus of 6 million IU, followed by 3 million IU every 8 hours. After the first day, the dosage will be adjusted based on kidney and liver function. This therapy will be administered for a total of 10 days.
There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to BVL-GSK098 and 2 subjects randomized to placebo.
Pharmaceutical and veterinary compositions for oral administration comprising a therapeutically effective amount of at least one coxib together with a therapeutically 5 effective amount of pentosan polysulfate or a pharmaceutically acceptable salt thereof are described. The compositions have application for the prophylaxis or treatment of pain and/or inflammation. There is also described a pharmaceutical or veterinary composition comprising a therapeutically effective amount of at least one coxib. The compositions in at least some forms may be lactose free and/or provided in a non 10 gelatin capsule. Further, there are provided methods for administration of a therapeutically effective amount of at least one coxib in combination with pentosan polysulfate or a pharmaceutically acceptable salt thereof for the prophylaxis or treatment of pain and/or inflammation. 0 OR OR 0 OR 0 OR 0 OR 0 OR 0 OR 0 OR OOR Q,0 OR OR OR OR OR OR R = SO 3Na 0ORO MeO a OR Hand OA Treatment Comparisons 150 Pentacoxib * Celecoxib Group (n = 5) Group (n =4) 1 50 -- 0 -. - -50 Cii0 Para er Clinical Parameter
Clear cell renal cell carcinoma (ccRCC) is a malignant tumor needs more effective treatments. TATA box-binding protein-associated factor RNA polymerase I subunit D (TAF1D) is a member of the selective factor 1 complex and functions in RNA polymerase I-dependent transcription. Higher TAF1D expression was found in ccRCC tumor tissues and indicated worse survival. Our study aimed to investigate the therapeutic potential of TAF1D in ccRCC. The proliferation and migration of ccRCC cells were significantly inhibited after TAF1D knockdown, while TAF1D overexpressing had opposite effects. Moreover, TAF1D knockdown induced cells to undergo G0/G1 cell cycle arrest and blockade of the epithelial-mesenchymal transition (EMT) process. Mechanistically, TAF1D affect the cell cycle and EMT through the PI3K/AKT/mTOR signaling pathway, thereby promoting the proliferation and metastasis of ccRCC cells in vivo and in vitro. The inhibitory effect of TAF1D knockdown could be reverted by the AKT activator SC79 in ccRCC cells, confirming this mechanism. Besides, TAF1D knockdown in ccRCC cells had a sensitizing effect on sunitinib and enhanced tumor cell inhibiting induced by sunitinib. In conclusion, TAF1D may be a promising target for the treatment of ccRCC and for overcoming sunitinib resistance.
POI is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. POI is characterized by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotropins and low estradiol.
This invention relates to the pharmaceutical field, specifically to a series of integrin blockers that present strong angiogenesis inhibiting performance, high integrin affinity and integrin-bonding capacity. This series of integrin blockers can be adopted in treatment of solid tumors and rheumatoid arthritis. Specifically, said series of integrin blockers include polypeptide I, polypeptide II and polypeptide III (see Seq. No.1, Seq. No.2 and Seq. No. 3) that can be adopted in treatment of solid tumors and rheumatoid arthritis. This invention also relates to application of these three integrin-blocking polypeptides in preparation of anti-tumor drugs, wherein the tumors that can be treated include those primary or secondary cancers originated from head and neck region or other organs such as brain, thyroid, esophagus, pancreas, lung, liver, stomach, breast, kidney, gallbladder, colon, rectum, ovary, cervix, uterus, prostate, bladder and testicle, as well as melanoma and sarcomas.